Shots:

• Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will be responsible for all development- regulatory- commercialization activities and its costs 
• In Mar’2010- GSK and Ionis collaborated on RNA therapies for rare and infectious diseases and granted GSK option to license and commercialize therapies at the clinical proof-of-concept
• Ionis’ antisense technology targets the process of producing a protein before it even begins and has developed a first treatment for SMA in adults & children and world's first RNA-targeted therapies for polyneuropathy in adults with hereditary transthyretin amyloidosis

Click here to­ read full press release/ article

Ref: PR Newswire | Image: GSK